白血病细胞ras癌基因产物p^(21)免疫细胞化学研究  

STUDY OF IMMUNOCYTOCHEMICAL RESULT OF THE RAS ONCOGENE PRODUCT p21 IN LEUKEMIC CELLS

作　　者：林东红 吕联煌[1,2] 张学敏[1,2] 

机构地区：[1]福建省血液病研究所 [2]福建医科大学检验系

出　　处：《中国免疫学杂志》1998年第5期342-344,共3页Chinese Journal of Immunology

摘　　要：应用ｒａｓｐ２１单克隆抗体免疫细胞化学法分析２８例急性髓细胞白血病和１５例急性淋巴细胞白血病，两者ｐ２１阳性率分别为３５７％和６７％，差别有显著性意义（Ｐ＜００５），ｐ２１主要在急性粒细胞白血病中表达。在１２例慢性粒细胞白血病（ＣＭＬ）中有５例ｐ２１阳性，占４１７％，推测ｒａｓ基因的扩增可能在ＣＭＬ的发展中起一定作用。免疫细胞化学结果显示：ｒａｓ基因的损伤并非累及白血病细胞的某一特定阶段或同一发展阶段的全部白血病细胞。ｒａｓ基因的扩增与白血病细胞的增殖、分化以及白血病患者的预后有关。By applying rasp21 monoclonal antibody immunocytochemical analysis of the ras oncogene protein p21 in leukemic cells,had found p21 positive in 10/28(35.7%) of AML,in 1/15(6.7%) of ALL.The difference of p21 positive rate was singnificant(P<005).The expression of rasp21 was mainly in acute myeloblastic leukemia.Among 12 patients with CML,5 of them were p21 positive(41.7%).It was speculated that the ras oncogene amplification may play some important role in the evolution of CML.Immunocytochemistry displayed that the ras oncogene does not always involve in some one stage leukemic cells or the all leukemic cells that belong to the same developing stage in morpholog.The amplification of ras oncogene may associate with the cell proliferation,differentiation and the prognosis of patients with leukemia.

关 键 词：白血病 RAS 癌基因 P21基因 免疫细胞化学 

分 类 号：R733.703[医药卫生—肿瘤]